AbCellera Biologics Inc.
ABCLUnited States
22 filed reports · 338 financial concepts · 1 earnings calls · 0 media appearances
Filed reports
22 reports · Jun 2021 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 16 | 2,316 | Jun 2021 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 5 | 2,190 | Dec 2021 to Dec 2025 |
| Annual · 10-K/ASEC EDGAR | 1 | 1 | Dec 2021 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 290 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 11, 2026 | 167 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 24, 2026 | 697 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 195 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 7, 2025 | 125 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 124 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 27, 2025 | 390 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 4, 2024 | 150 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 134 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 145 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 20, 2024 | 409 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 2, 2023 | 152 | Open |
Financial data
338 concepts · 4,507 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial333 concepts · 4,377 facts · Dec 2019 to Aug 2026
- Cash and cash equivalents at carrying value40 · Dec 2020 to Jun 2026
- Stockholders equity (US GAAP)34 · Dec 2019 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value33 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations33 · Dec 2019 to Jun 2026
- Contract with customer liability33 · Dec 2019 to Jun 2026
- Net income loss33 · Dec 2019 to Jun 2026
- Allocated share based compensation expense32 · Dec 2019 to Jun 2026
- Comprehensive income net of tax32 · Dec 2019 to Jun 2026
- Contract with customer liability revenue recognized32 · Dec 2019 to Jun 2026
- Depreciation32 · Dec 2019 to Jun 2026
- Grants and incentives32 · Dec 2019 to Jun 2026
- Net income loss available to common stockholders basic32 · Dec 2019 to Jun 2026
- Net income loss available to common stockholders diluted32 · Dec 2019 to Jun 2026
- Nonoperating income expense32 · Dec 2019 to Jun 2026
- Operating expenses (US GAAP)32 · Dec 2019 to Jun 2026
- Operating income loss32 · Dec 2019 to Jun 2026
- Research and development expense32 · Dec 2019 to Jun 2026
- Revenue32 · Dec 2019 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect31 · Dec 2019 to Jun 2026
- Increase decrease in deferred revenue31 · Dec 2019 to Jun 2026
- Net cash provided by used in financing activities31 · Dec 2019 to Jun 2026
- Net cash provided by used in investing activities31 · Dec 2019 to Jun 2026
- Net cash provided by used in operating activities31 · Dec 2019 to Jun 2026
- Operating lease right of use asset amortization expense31 · Dec 2019 to Jun 2026
Product2 concepts · 110 facts · Dec 2019 to Jun 2026
- Revenue106 · Dec 2019 to Jun 2026
- Royalty Revenue4 · Dec 2020 to Dec 2023
Geography3 concepts · 20 facts · Dec 2021 to Dec 2025
- Revenue10 · Dec 2021 to Dec 2025
- CANADA5 · Dec 2021 to Dec 2025
- Other Foreign Countries5 · Dec 2021 to Dec 2025
Segments
130 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service5 members · 110 facts
- Research Fees32 · Dec 2019 to Jun 2026
- Milestone Payments28 · Jun 2020 to Dec 2025
- License25 · Mar 2021 to Dec 2025
- Royalty21 · Dec 2020 to Dec 2024
- Licensing And Royalty Revenue4 · Mar 2025 to Jun 2026
Statement geographical3 members · 20 facts
- CA10 · Dec 2021 to Dec 2025
- Other Foreign Countries5 · Dec 2021 to Dec 2025
- US5 · Dec 2021 to Dec 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
1 calls · Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.